Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIPC: TLR9 Immunotherapy for Peritoneal Carcinomatosis
NCT07658196Phase 1Recruiting
- Sponsor
- Brown University
- Start
- Aug 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ACM-CpG in colorectal adenocarcinoma, appendiceal adenocarcinoma, primary peritoneal cancer (PPC) and 1 more, sponsored by Brown University. Primary endpoint: Incidence of Treatment-Emergent Adverse Events. Started Aug 2026; status: recruiting.
02
Drugs
ACM-CpG
03
Conditions
colorectal adenocarcinomaappendiceal adenocarcinomaprimary peritoneal cancer (PPC)malignant ascites
Beyond the preview
Go deeper on NCT07658196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07658196.